JP2019515908A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019515908A5 JP2019515908A5 JP2018554585A JP2018554585A JP2019515908A5 JP 2019515908 A5 JP2019515908 A5 JP 2019515908A5 JP 2018554585 A JP2018554585 A JP 2018554585A JP 2018554585 A JP2018554585 A JP 2018554585A JP 2019515908 A5 JP2019515908 A5 JP 2019515908A5
- Authority
- JP
- Japan
- Prior art keywords
- independently hydrogen
- compound
- group
- hydrogen
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 32
- 239000001257 hydrogen Substances 0.000 claims 32
- 150000002431 hydrogen Chemical class 0.000 claims 30
- 150000001875 compounds Chemical class 0.000 claims 20
- 150000003839 salts Chemical class 0.000 claims 12
- 239000011780 sodium chloride Substances 0.000 claims 12
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 8
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 8
- 229940000425 combination drugs Drugs 0.000 claims 6
- 230000000875 corresponding Effects 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000009118 salvage therapy Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
- 0 C*C(C(C(C1C(C)O)O)O)OC1C(O)=O Chemical compound C*C(C(C(C1C(C)O)O)O)OC1C(O)=O 0.000 description 3
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021140920A JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325200P | 2016-04-20 | 2016-04-20 | |
| US62/325,200 | 2016-04-20 | ||
| PCT/US2017/028646 WO2017184871A1 (en) | 2016-04-20 | 2017-04-20 | Carbidopa and l-dopa prodrugs and methods of use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021140920A Division JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019515908A JP2019515908A (ja) | 2019-06-13 |
| JP2019515908A5 true JP2019515908A5 (US20070167479A1-20070719-C00034.png) | 2020-06-18 |
Family
ID=58668985
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554585A Pending JP2019515908A (ja) | 2016-04-20 | 2017-04-20 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2021140920A Pending JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A Pending JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021140920A Pending JP2022000428A (ja) | 2016-04-20 | 2021-08-31 | カルビドパ及びｌ−ドパプロドラッグ並びに使用方法 |
| JP2023179367A Pending JP2024020212A (ja) | 2016-04-20 | 2023-10-18 | カルビドパ及びｌ－ドパプロドラッグ並びに使用方法 |
Country Status (4)
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102537018B1 (ko) | 2014-10-21 | 2023-05-30 | 애브비 인코포레이티드 | 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 |
| WO2019097120A1 (en) | 2017-11-16 | 2019-05-23 | Orion Corporation | New use and pharmaceutical dosage forms |
| SG11202004461YA (en) | 2017-11-24 | 2020-06-29 | H Lundbeck As | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| JP7346571B2 (ja) * | 2018-12-05 | 2023-09-19 | ビー．ジー．ネゲブ テクノロジーズ アンド アプリケーションズ リミテッド， アット ベン‐グリオン ユニバーシティー | ドーパミン応答性障害の治療のための糖にコンジュゲートされたｌ－ｄｏｐａ及び／またはｄｏｐａデカルボキシラーゼ阻害剤 |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| JP2024010252A (ja) | 2021-03-10 | 2024-01-24 | 田辺三菱製薬株式会社 | パーキンソン病治療のための組合せ医薬 |
| WO2024104331A1 (zh) * | 2022-11-14 | 2024-05-23 | 江苏恒瑞医药股份有限公司 | 一种左旋多巴的前药 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE118216T1 (de) * | 1989-04-20 | 1995-02-15 | Zambon Spa | Dopamin-medikament-vorstufe. |
| GB9102812D0 (en) * | 1991-02-11 | 1991-03-27 | Enzymatix Ltd | Compounds |
| IT1255471B (it) * | 1992-07-30 | 1995-11-02 | Zambon Spa | Derivati di catecolammine,processo per la loro preparazione e composizioni farmaceutiche che li contengono |
| US6204257B1 (en) * | 1998-08-07 | 2001-03-20 | Universtiy Of Kansas | Water soluble prodrugs of hindered alcohols |
| CN1671724A (zh) * | 2002-06-20 | 2005-09-21 | 日本水产株式会社 | 前药、其作为医药的应用及其制法 |
| WO2004052841A1 (en) * | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
| US20050070608A1 (en) * | 2003-08-29 | 2005-03-31 | Julius Remenar | Pharmaceutical compositions and method of using levodopa and carbidopa |
| JP2007509971A (ja) * | 2003-10-31 | 2007-04-19 | アルザ・コーポレーシヨン | メトホルミンの増加された吸収のための組成物及び投与形態物 |
| JP4781352B2 (ja) * | 2004-06-04 | 2011-09-28 | ゼノポート，インコーポレーテッド | レボドパプロドラッグおよびその組成物ならびにその使用 |
| KR101229431B1 (ko) * | 2004-07-06 | 2013-02-04 | 아보트 러보러터리즈 | Ｈｉｖ 프로테아제 억제제의 프로드럭 |
| CA2673336A1 (en) * | 2006-12-21 | 2008-06-26 | Xenoport, Inc. | Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use |
| JP5757864B2 (ja) * | 2008-05-20 | 2015-08-05 | ニューロジェシックス， インコーポレイテッド | 水溶性アセトアミノフェン類似体 |
| ES2776734T3 (es) * | 2010-11-15 | 2020-07-31 | Neuroderm Ltd | Administración continua de L-dopa, inhibidores de dopa descarboxilasa, inhibidores de catecol-o-metil transferasa y composiciones para ello |
| KR102537018B1 (ko) * | 2014-10-21 | 2023-05-30 | 애브비 인코포레이티드 | 카르비도파 및 l-도파 프로드럭 및 파킨슨병을 치료하기 위한 이들의 용도 |
-
2017
- 2017-04-20 EP EP17721269.3A patent/EP3445346A1/en not_active Withdrawn
- 2017-04-20 JP JP2018554585A patent/JP2019515908A/ja active Pending
- 2017-04-20 EP EP23192663.5A patent/EP4295909A3/en active Pending
- 2017-04-20 US US16/164,073 patent/US20190224220A1/en not_active Abandoned
- 2017-04-20 WO PCT/US2017/028646 patent/WO2017184871A1/en active Application Filing
-
2021
- 2021-08-31 JP JP2021140920A patent/JP2022000428A/ja active Pending
-
2023
- 2023-10-18 JP JP2023179367A patent/JP2024020212A/ja active Pending
